OS Therapies Incorporated (OSTX) AMEX
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
| Previous Close | 1.25 |
| Open | 1.27 |
| Day High | 1.29 |
| Day Low | 1.23 |
| 52-Week High | 2.25 |
| 52-Week Low | 1.15 |
| Volume | 141,925 |
| Average Volume | 584,332 |
| Market Cap | 58.51M |
| PE | -1.23 |
| EPS | -1.02 |
| Moving Average 50 Days | 1.6 |
| Moving Average 200 Days | 1.57 |
| Change | 0 |
OS Therapies Announces FDA OST-HER2 Type D Meeting Elevated to Type B Pre-BLA Meeting
Newsfile
Mar 09, 2026 11:40 AM GMT
FDA's elevated meeting status signals transition from biomarker data discussions to Accelerated Approval discussionsOS Therapies on track to complete clinical data submission by the end of Q1 2026New York, New York--(Newsfile Corp. - March 9, 2026) -
OS Therapies Provides Global Regulatory Update for OST-HER2 in Recurrent, Fully Resected, Pulmonary Metstatic Osteosarcoma
Newsfile
Feb 17, 2026 11:00 AM GMT
Additional forthcoming biomarker data from human trial expected to further characterize immune pathway activation and its relationship to clinical outcomesU.S., U.K. and European osteosarcoma key opinion leaders assembling to review clinical & biomar
OS Therapies Applauds Reauthorization of Pediatric Priority Review Voucher Program to Advance Breakthrough Osteosarcoma Immunotherapies
Newsfile
Feb 04, 2026 5:45 PM GMT
New York, New York--(Newsfile Corp. - February 4, 2026) - OS Therapies Inc. (NYSE American: OSTX) ("OS Therapies" or "the Company"), the world leader in listeria-based cancer immunotherapies, is honored to celebrate the passage of the Mikaela Naylon